Related references
Note: Only part of the references are listed.Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer
Adriaan Vanderstichele et al.
GYNECOLOGIC ONCOLOGY (2022)
A dimerization-dependent mechanism regulates enzymatic activation and nuclear entry of PLK1
Monika Raab et al.
ONCOGENE (2022)
Present and Future Perspective on PLK1 Inhibition in Cancer Treatment
Michela Chiappa et al.
FRONTIERS IN ONCOLOGY (2022)
Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models
Camilla Coulson-Gilmer et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)
Modulation of KRAS Mutant by Inhibiting PLK1 Kinase in Cancer Therapeutics
Robert B. Kargbo
ACS Medicinal Chemistry Letters (2021)
Boosting the apoptotic response of high-grade serous ovarian cancers withCCNE1amplification to paclitaxelin vitroby targeting APC/C and the pro-survival protein MCL-1
Monika Raab et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
ERK/MAPK signalling pathway and tumorigenesis
Yan-Jun Guo et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2020)
PARP inhibitor resistance: the underlying mechanisms and clinical implications
He Li et al.
MOLECULAR CANCER (2020)
Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
Hyoung Kim et al.
NATURE COMMUNICATIONS (2020)
The Prognostic Relevance of the Proliferation Markers Ki-67 and Plk1 in Early-Stage Ovarian Cancer Patients With Serous, Low-Grade Carcinoma Based on mRNA and Protein Expression
Franz Roedel et al.
FRONTIERS IN ONCOLOGY (2020)
DNA Damage Baseline Predicts Resilience to Space Radiation and Radiotherapy
Eloise Pariset et al.
CELL REPORTS (2020)
Blocking Mitotic Exit of Ovarian Cancer Cells by Pharmaceutical Inhibition of the Anaphase-Promoting Complex Reduces Chromosomal Instability
Monika Raab et al.
NEOPLASIA (2019)
Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy
Yong Fang et al.
CANCER CELL (2019)
PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells
Sylvie M. Noordermeer et al.
TRENDS IN CELL BIOLOGY (2019)
MicroRNA-508 suppresses epithelial-mesenchymal transition, migration, and invasion of ovarian cancer cells through the MAPK1/ERK signaling pathway
Lan Hong et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2018)
Synthetic lethality in CCNE1-amplified high grade serous ovarian cancer through combined inhibition of polo-like kinase 1 and microtubule dynamics
Sabrina Noack et al.
Oncotarget (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
International patterns and trends in ovarian cancer incidence, overall and by histologic subtype
S. B. Coburn et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
The multifaceted roles of PARP1 in DNA repair and chromatin remodelling
Arnab Ray Chaudhuri et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2017)
Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers
Chaoyang Sun et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
PLK1, A Potential Target for Cancer Therapy
Zhixian Liu et al.
TRANSLATIONAL ONCOLOGY (2017)
Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property
Chandra Bhushan Prasad et al.
SCIENTIFIC REPORTS (2017)
Plk1 Phosphorylation of Mre11 Antagonizes the DNA Damage Response
Zhiguo Li et al.
CANCER RESEARCH (2017)
Ligand stimulation of CD95 induces activation of Plk3 followed by phosphorylation of caspase-8
Christina Helmke et al.
CELL RESEARCH (2016)
Nek1 Regulates Rad54 to Orchestrate Homologous Recombination and Replication Fork Stability
Julian Spies et al.
MOLECULAR CELL (2016)
Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK
Jieqiong Wang et al.
NATURE COMMUNICATIONS (2016)
FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
Geoffrey Kim et al.
CLINICAL CANCER RESEARCH (2015)
FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication
Jaime Prat
JOURNAL OF GYNECOLOGIC ONCOLOGY (2015)
Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination
Philip Jones et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis
Ruitao Zhang et al.
ONCOLOGY REPORTS (2015)
Ovarian cancer standard of care: are there real alternatives?
Chiara Della Pepa et al.
CHINESE JOURNAL OF CANCER (2015)
PARP1 Inhibitors: Antitumor Drug Design
N. V. Malyuchenko et al.
ACTA NATURAE (2015)
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
David D. Bowtell et al.
NATURE REVIEWS CANCER (2015)
Polo-like kinase-1 in DNA damage response
Sun-Yi Hyun et al.
BMB REPORTS (2014)
Plk1 Inhibition Enhances the Efficacy of Androgen Signaling Blockade in Castration-Resistant Prostate Cancer
Zhe Zhang et al.
CANCER RESEARCH (2014)
DNA breaks and chromosomal aberrations arise when replication meets base excision repair
Michael Ensminger et al.
JOURNAL OF CELL BIOLOGY (2014)
Phase I/Ib Study of Olaparib and Carboplatin in BRCA1 or BRCA2 Mutation-Associated Breast or Ovarian Cancer With Biomarker Analyses
Jung-Min Lee et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Plk1-targeted therapies in TP53-or RAS-mutated cancer
Hyungshin Yim et al.
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH (2014)
Polo-like kinase 1 regulates the stability of the mitotic centromere-associated kinesin in mitosis
Mourad Sanhaji et al.
ONCOTARGET (2014)
Plk1: unexpected roles in DNA replication
Ranadip Mandal et al.
CELL RESEARCH (2013)
KRAS and MAPK1 Gene Amplification in Type II Ovarian Carcinomas
Mohammed Tanjimur Rahman et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
Oncogenic KRAS and BRAF activation of the MEK/ERK signaling pathway promotes expression of dual-specificity phosphatase 4 (DUSP4/MKP2) resulting in nuclear ERK1/2 inhibition
S. Cagnol et al.
ONCOGENE (2013)
Evaluating cell lines as tumour models by comparison of genomic profiles
Silvia Domcke et al.
NATURE COMMUNICATIONS (2013)
Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients
Balazs Gyoerffy et al.
ENDOCRINE-RELATED CANCER (2012)
Ovarian low-grade serous carcinoma: A comprehensive update
Ivan Diaz-Padilla et al.
GYNECOLOGIC ONCOLOGY (2012)
Plk1 and CK2 Act in Concert to Regulate Rad51 during DNA Double Strand Break Repair
Keiko Yata et al.
MOLECULAR CELL (2012)
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Jonathan Ledermann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Switching Polo-like kinase-1 on and off in time and space
Wytse Bruinsma et al.
TRENDS IN BIOCHEMICAL SCIENCES (2012)
Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-Shifting the paradigm
Robert J. Kurman et al.
HUMAN PATHOLOGY (2011)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
Polo-like kinase1 (Plk1) knockdown enhances cisplatin chemosensitivity via up-regulation of p73α in p53 mutant human epidermoid squamous carcinoma cells
Shilpa Tyagi et al.
BIOCHEMICAL PHARMACOLOGY (2010)
Residual γH2AX foci as an indication of lethal DNA lesions
Judit P. Banath et al.
BMC CANCER (2010)
Polo-like Kinase 1 (Plk1) as a Novel Drug Target in Chronic Myeloid Leukemia: Overriding Imatinib Resistance with the Plk1 Inhibitor BI 2536
Karoline V. Gleixner et al.
CANCER RESEARCH (2010)
A Fine-Needle Aspirate-Based Vulnerability Assay Identifies Polo-Like Kinase 1 as a Mediator of Gemcitabine Resistance in Pancreatic Cancer
Antonio Jimeno et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing
Tom Walsh et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways
Minli Wang et al.
NUCLEIC ACIDS RESEARCH (2006)
REporting recommendations for tumor MARKer prognostic studies (REMARK)
Lisa M. McShane et al.
BREAST CANCER RESEARCH AND TREATMENT (2006)
Polo-like kinases - A team in control of the division
Barbara C. M. van de Weerdt et al.
CELL CYCLE (2006)
Cooperation of ERK and SCFSkp2 for MKP-1 destruction provides a positive feedback regulation of proliferating signaling
YW Lin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Polo-like kinases and oncogenesis
F Eckerdt et al.
ONCOGENE (2005)
Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma
W Weichert et al.
BRITISH JOURNAL OF CANCER (2004)
Polo-like kinase-1 controls recovery from a G2 DNA damage-induced arrest in mammalian cells
MATM van Vugt et al.
MOLECULAR CELL (2004)
Poly(ADP-ribose) is required for spindle assembly and structure
P Chang et al.
NATURE (2004)
Adaptation of a DNA replication checkpoint response depends upon inactivation of Claspin by the Polo-like kinase
HY Yoo et al.
CELL (2004)
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study
RF Ozols et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Polo-like kinase-1 is a target of the DNA damage checkpoint
VAJ Smits et al.
NATURE CELL BIOLOGY (2000)
Share Paper
